Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glitazone safety assessment continues

Executive Summary

FDA is continuing to evaluate the safety of Warner-Lambert's Rezulin, SmithKline Beecham's Avandia and Lilly/Takeda's Actos "to more fully characterize the relative hepatic safety profile of these drugs." FDA noted that "comparative analyses remain preliminary" for the glitazones due to the short time Avandia and Actos have been on the market. "A definitive comparative hepatic safety conclusion has not been made by FDA at this time," the agency said in a statement. SB CEO-designate Jean-Pierre Garnier recently said that enough patients have been treated with Avandia and safety is no longer an issue. SB reports over 520,000 patients have been prescribed Avandia. Rezulin labeling was revised to recommend liver monitoring after use in 500,000 patients. According to IMS Health data, 309,000 Rezulin prescriptions, 268,000 Avandia prescriptions and 145,000 Actos prescriptions were written in January

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel